arrow
S

Simon J. Dovedi

b oncology r&d, astrazeneca, cambridge, ukcorrespondencesimon.dovedi@astrazeneca.com view further author information
H指数:29
被引数:4,629

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

IL-2-armored肽-主要组织相容性I类双特异性抗体重定向抗病毒效应记忆CD8 T细胞以诱导有效的抗癌细胞毒活性和有限的细胞因子释放

MABS
IF7.3
2024-08-280
OAAI
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity
2024-01-2423
OAAI
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
2024-01-112
OAAI
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

靶向DNA损伤反应成分可在ATM缺陷的癌细胞中诱导STING依赖性I型IFN反应增强,并驱动树突状细胞活化

2022-09-1320
OA
A LAT-Based Signaling Complex in the Immunological Synapse as Determined with Live Cell Imaging Is Less Stable in T Cells with Regulatory Capability

通过活细胞成像确定的免疫突触中基于LAT的信号传导复合物在具有调节能力的T细胞中不太稳定

CELLS
IF5.2
2021-02-171
OAAI
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

增强PD-1活化T细胞CTLA4阻断的单价双特异性PD-1/CTLA4抗体的设计和功效

2021-01-08123
PRE
CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?
2020-09-010
OAAI